NCT05980416 2025-11-14Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2Elevation OncologyPhase 1 Terminated88 enrolled 18 charts
NCT02564198 2021-08-17A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsEli Lilly and CompanyPhase 1 Completed29 enrolled 12 charts
NCT01017731 2015-06-10Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval ChangesEli Lilly and CompanyPhase 2 Completed68 enrolled 13 charts
NCT00627042 2014-10-08Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With ChemotherapyEli Lilly and CompanyPhase 2 Completed42 enrolled 19 charts
NCT01246960 2014-10-08A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerEli Lilly and CompanyPhase 2 Completed168 enrolled 16 charts